Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Polo-like kinase1 (Plk1) knockdown enhances cisplatin chemosensitivity via up-regulation of p73α in p53 mutant human epidermoid squamous carcinoma cells.

Biochemical pharmacology - 1 Nov 2010

Tyagi Shilpa, Bhui Kulpreet, Singh Richa, Singh Madhulika, Raisuddin Sheikh, Shukla Yogeshwer

Abstract excerpt

Polo-like kinase 1 (Plk1), a critical regulator of mitotic entry, progression and exit, has been shown to be involved in a variety of cancers and thus is becoming an attractive target for cancer management. In case of DNA damage, Plk1 not only inhibits p53 independent apoptosis by dysfunctioning...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Squamous Cell
Share to Cell Cycle Proteins
Share to Cisplatin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, p53

Share to Polo-Like Kinase 1

Share to RNA Interference

Share to Tumor Protein p73

Share to Tumor Suppressor Proteins

Source

Identifiers

PMID: 20655883
DOI: 10.1016/j.bcp.2010.07.025

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20655883-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Polo-like kinase1 (Plk1) knockdown enhances cisplatin chemosensitivity via up-regulation of p73α in p53 mutant human epidermoid squamous carcinoma cells.PMID 20655883Read ↗

Polo-like kinase 1 (Plk1) in non-melanoma skin cancersSemantic proximity Read ↗

Present and Future Perspective on PLK1 Inhibition in Cancer TreatmentSemantic proximity Read ↗

Polo-like kinase inhibitors: an emerging opportunity for cancer therapeuticsSemantic proximity Read ↗

Polo-like Kinase 1 as an emerging drug target: structure, function and therapeutic implicationsSemantic proximity Read ↗

Battle of the eternal rivals: restoring functional p53 and inhibiting Polo-like kinase 1 as cancer therapySemantic proximity Read ↗

Targeting Polo-like Kinase in Cancer TherapySemantic proximity Read ↗

The Role of Polo-like Kinase 1 in Carcinogenesis: Cause or Consequence?Semantic proximity Read ↗

Inhibition of Polo-like kinase 1 (PLK1) triggers cell apoptosis via ROS-caused mitochondrial dysfunction in colorectal carcinomaSemantic proximity Read ↗

Polo-like kinase 1 is a potential therapeutic target in human melanoma.Semantic proximity Read ↗

PLK-1 Targeted Inhibitors and Their Potential against TumorigenesisSemantic proximity Read ↗

The balance of Polo-like kinase 1 in tumorigenesisSemantic proximity Read ↗

Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.